Dr Shereef Elmoamly
Qualifications
MB.BCh, Msc, MD, MRCP, FRCPath
GMC number: 7189434
Practising since: 2001
Specialties
Haematology
Consultation times
- Saturday morning
- Overview
About
Dr Shereef Elmoamly is a consultant Haematologist at Russell’s Hall Hospital since 2020. He has completed his postgraduate specialty training in West Midlands Deanery after completing clinical fellowship at Manchester royal infirmary. He undertook his MD research in Hemato-oncology and venous thromboembolism.
Dr Elmoamly is the chemotherapy lead in the Dudley group NHS trust. His main interests are general haematology, malignant haematology, and venous thrombosis.
He treats an average of 60-70 outpatients and 15-20 inpatients per week in a busy haematology service delivered at Georgina unit at Russell’s Hall hospital with conditions including blood cancers, anaemia, clotting disorders, bleeding tendency and bone marrow transplant. He also covers the haematology lab with reporting blood films and bone marrow aspirates.
Dr Elmoamly takes part in clinical trials in haemato-oncology, being a principal investigator or co-investigator for several trials at his institution. He has many publications in peer reviewed medical journals.
In addition to the treatments listed, Mr Elmoamly also offers:
- Bone marrow aspirate and trephine
- Venesection
- Chemotherapy
- Blood transfusion.
Special interests
• Haemochromatosis
Languages spoken
English
Treatments and tests offered by Dr Shereef Elmoamly at Nuffield Health
- Blood test
- Haemato-oncology
- Phlebotomy
- Haematology profiles
Locations Dr Shereef Elmoamly works with
Related experience
Research
- MSc degree in Internal Medicine; Thesis title: Multitransfusion and Ferrokinetics in Cases with Myelodysplastic Syndrome with Special Emphasis on Cardiac Functions.
- MSc degree in Clinical Haematology; Essay title: Epigenetics in haematologic disorders and role of epigenetic modifiers as targeted therapy of haematologic malignancies.
- MD degree; Thesis title: Incidence of Venous Thromboembolism (VTE) in patients with Haematological Malignancies and Relation to laboratory biomarkers.
Publications including (full list can be found on https://www.researchgate.net/profile/Shereef-Elmoamly )
-Elmoamly, S., Obici, L. (2022). Amyloidosis: Pathogenesis, Types, and Diagnosis. In: Ragab, G., Quartuccio, L., Goubran, H. (eds) Paraproteinemia and Related Disorders. Springer, Cham.
- Elmoamly S, Mattar M, Yacoub M F, & Afif A. Can Biomarkers of Coagulation, Platelet Activation, and Inflammation Predict Venous Thromboembolism in Patients with Haematological Malignancies? Acta haematol, 2019; 141:245-253. (DOI: 10.1159/000496914).
-Murthy V, Kapuge N, Kartsios C, Ewing J, Xenou E, Kaparou M, Elmoamly S, Nikolousis E; Azacitidine Improves Outcome in Patients with MDS and AML with High Risk Cytogenetics - a Single Center Experience. Blood 2018; 132 (Supplement 1): 5529. doi: https://doi.org/10.1182/blood-2018-99-109774
- Elmoamly S & Afif A. Can biomarkers of coagulation, platelet activation, and inflammation predict mortality in patients with haematological malignancies? Hematology. 2018: 23:2, 89-95. (DOI: 10.1080/10245332.2017.1365458).
Memberships
- Royal College of Pathologists
- Royal College of Physicians
- British Society of Haematology
- British medical association
Other posts held
- Consultant Haematologist at Dudley Group NHS Foundation Trust
Declaration
Dr Shereef Elmoamly does not hold a share or financial interest in this hospital, another Nuffield Health hospital or the company.
Dr Shereef Elmoamly does not have a share or financial interest in equipment used at this hospital or another Nuffield Health hospital.
Dr Shereef Elmoamly does not hold any paid advisory role(s) at this hospital or on behalf of Nuffield Health.